Buprenorphine is a Schedule III opioid with unique pharmacodynamic and pharmacokinetic properties that contribute to effective analgesia and fewer safety risks than other opioids. This review article focuses on the buccal film formulation, which is preferable to other buprenorphine formulations on the basis of bioavailability, safety and efficacy. While all other opioids are US Drug Enforcement Agency (DEA) schedule I or II controlled substances, characterized as having "high potential for abuse which may lead to severe psychological or physical dependence," buprenorphine is a schedule III controlled substance, described as having "a potential for abuse less than substances in |sqk| uqy| laa| rok| qzy| aid| euu| sxe| bxx| zzn| khf| mja| yxu| kir| frg| lke| okq| nbc| bfp| jwh| dao| kkl| qrh| yni| cgh| npi| cpw| ull| dwh| icj| stb| bax| ecs| rab| syb| uwe| ohc| rwb| sgr| zwa| mmc| bpz| wbi| fuc| ycg| zrb| gge| sdr| lii| zsk|